Shire says it's sitting on a $3B pipeline with M&A on tap

December 10, 2014 2:20 PM

3 0

Shire, settling into life on its own after a failed merger with AbbVie ($ABBV), believes its in-development drugs can bring in a combined $3 billion in sales by 2020, sharpening its focus on rare diseases and keeping an eye out for bolt-on acquisitions.

At its R&D day in New York, Shire ($SHPG) pulled back the veil on its pipeline, pointing to a company-record 22 candidates in clinical development and heralding a new collaboration that will broaden its work in cystic fibrosis.

Read more

To category page

Loading...